Owen N E, Gunn R B
Biochim Biophys Acta. 1983 Jan 5;727(1):213-6. doi: 10.1016/0005-2736(83)90387-5.
The kinetic mechanism of chlorpromazine inhibition of erythrocyte hexose transport was investigated using the non-metabolizable glucose analog 3-O-methylglucose. It was found that chlorpromazine added to the external medium is a non-competitive inhibitor of both equilibrium exchange and net 3-O-methylglucose transport at pH 7.8, 15 degrees C. The Ki for equilibrium exchange is 76 +/- 21 microM. When net efflux and equilibrium exchange were measured on the same population of cells the equilibrium exchange was 2.5-times the maximum net efflux. The percent reduction of 3-O-methylglucose flux by chlorpromazine is dependent upon chlorpromazine concentration and not 3-O-methylglucose concentration as expected for a non-competitive inhibitor. Equilibrium exchange and net efflux show the same extent of inhibition at each concentration of chlorpromazine evaluated. These results suggest that exchange and net efflux of 3-O-methylglucose in the human erythrocyte may share a common transport system.
利用不可代谢的葡萄糖类似物3-O-甲基葡萄糖,研究了氯丙嗪抑制红细胞己糖转运的动力学机制。发现在pH 7.8、15℃条件下,添加到外部介质中的氯丙嗪是平衡交换和净3-O-甲基葡萄糖转运的非竞争性抑制剂。平衡交换的Ki为76±21微摩尔。当对同一群细胞测量净流出和平衡交换时,平衡交换是最大净流出的2.5倍。氯丙嗪使3-O-甲基葡萄糖通量降低的百分比取决于氯丙嗪的浓度,而不像非竞争性抑制剂预期的那样取决于3-O-甲基葡萄糖的浓度。在评估的每个氯丙嗪浓度下,平衡交换和净流出显示出相同程度的抑制。这些结果表明,人红细胞中3-O-甲基葡萄糖的交换和净流出可能共享一个共同的转运系统。